Skip to main content
TipRanks
Go Ultimate75% OFF

SMS Pharmaceuticals Limited (SMSPHARMA) AI Stock Analysis

3 Followers
IN:SMSPHARMA

SMS Pharmaceuticals Limited

(NSE:SMSPHARMA)

Select Model
Rating:74Outperform
Price Target:INR 570.00â–²(18.17% Upside)
Action:reiterated
Date:09/19/26

SMS Pharmaceuticals secures a solid overall score driven by highly bullish technical momentum, surging profitability, and a deleveraging balance sheet. The company is in a strong expansion phase, but investors should monitor its premium valuation multiple and persistently negative free cash flow, which remain the primary balancing risks.

Positive Factors
Improving Balance SheetLower debt alongside a larger equity base improves financial resilience and reduces balance-sheet pressure. This gives SMS Pharmaceuticals more flexibility to fund operations and strategic investment, while making the company better positioned to withstand earnings volatility over the next several quarters.
Negative Factors
Weak Free Cash FlowPersistent negative free cash flow means reported earnings are not consistently converting into cash available for reinvestment, debt reduction, or distributions. The sharp FY2026 deterioration raises questions about the cash demands of operations and capital spending, limiting financial flexibility.

SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)

-25%0%25%50%75%100%IN:SMSPHARMA+76.19%INDA-4.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 44.70B
Dividend Yield
0.08%
Average Volume (3M)
39.91K
Price to Earnings (P/E)
38.0
Beta (1Y)
1.08
Revenue Growth
12.96%
EPS Growth
32.16%
Country
India
Employees
1,617
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

SMS Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of AP...

SMS Pharmaceuticals Limited Financial Statement Overview

Summary

Robust revenue and profit growth paired with a deleveraging balance sheet are major strengths, though persistently negative free cash flow driven by heavy capital reinvestment poses a liquidity risk.

Income Statement

88Very Positive

Balance Sheet

85Very Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.73B8.87B7.83B7.09B5.22B5.15B
Gross Profit2.73B1.75B1.45B2.11B1.29B1.81B
EBITDA1.97B1.71B1.45B1.18B593.89M1.20B
Net Income1.17B1.02B691.36M498.26M-70.59M622.20M
Balance Sheet
Total Assets14.61B13.62B11.53B10.34B8.80B8.60B
Cash, Cash Equivalents and Short-Term Investments363.13M460.75M415.86M361.16M73.78M465.83M
Total Debt3.49B3.65B3.11B2.81B2.54B2.63B
Total Liabilities6.18B5.77B5.13B4.98B4.19B3.89B
Stockholders Equity8.43B7.86B6.40B5.36B4.61B4.70B
Cash Flow
Free Cash Flow0-926.46M-588.57M-20.35M-74.71M129.86M
Operating Cash Flow0379.12M645.23M501.25M224.50M402.34M
Investing Cash Flow0-1.32B-1.24B-520.72M-296.86M-271.53M
Financing Cash Flow0981.46M644.32M306.79M-319.69M-69.21M

SMS Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price482.35

Price Trends

50DMA462.45Positive
100DMA421.37Positive
200DMA400.73Positive

Market Momentum

MACD11.17Positive
RSI50.55Neutral
STOCH11.63Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Neutral. The current price of 482.35 is below the 20-day moving average (MA) of 487.00, above the 50-day MA of 462.45, and above the 200-day MA of 400.73, indicating a neutral trend. The MACD of 11.17 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 11.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SMSPHARMA.

SMS Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:SMSPHARMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SMSPHARMAIN:SMSPHARMA74OutperformINR 45.17B38.02―0.08%12.96%32.16%
IN:MARKSANSIN:MARKSANS69NeutralINR 135.56B24.19―0.30%24.20%59.18%
IN:GLANDIN:GLAND66NeutralINR 543.06B43.92―0.61%21.90%56.28%
IN:SENORESIN:SENORES63NeutralINR 51.14B36.50――39.71%53.21%
IN:KOPRANIN:KOPRAN60NeutralINR 12.88B32.81―1.12%34.11%123.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:NGLFINEIN:NGLFINE46NeutralINR 17.21B26.88―0.06%40.66%208.52%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%IN:SMSPHARMAIN:GLANDIN:KOPRANIN:MARKSANSIN:NGLFINEIN:SENORESDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SMSPHARMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SMSPHARMASMS Pharmaceuticals Limited482.35210.7877.62%
IN:GLANDGland Pharma Ltd.3291.051513.4585.14%
IN:KOPRANKopran Limited266.45144.42118.35%
IN:MARKSANSMarksans Pharma Limited299.15110.6258.68%
IN:NGLFINENGL Fine-Chem Ltd.2785.851460.64110.22%
IN:SENORESSenores Pharmaceuticals Ltd.1110.35316.1539.81%

SMS Pharmaceuticals Limited Corporate Events

SMS Pharmaceuticals wins tax appeal; Rs 45.63 crore demand vacated

Oct 31, 2026

SMS Pharmaceuticals Limited has announced that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has allowed its appeal against an income tax assessment order for Assessment Year 2023-24. The appellate order under Section 250...

SMS Pharmaceuticals’ tax appeal dismissed; reduced demand upheld

Oct 31, 2026

SMS Pharmaceuticals Limited has disclosed that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has dismissed the company’s appeal against an earlier assessment order for the 2018-19 financial year. The case stems from a tax...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026